Main Street Capital Co. (MAIN) Given Consensus Rating of “Hold” by Brokerages

Main Street Capital Co. (NYSE:MAIN) has been assigned an average recommendation of “Hold” from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $38.98.

Several equities analysts have weighed in on MAIN shares. Zacks Investment Research raised Main Street Capital from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research note on Thursday. ValuEngine downgraded Main Street Capital from a “buy” rating to a “hold” rating in a report on Monday, February 5th. Finally, National Securities upgraded Main Street Capital from a “sell” rating to a “neutral” rating and increased their price objective for the stock from $33.00 to $35.00 in a report on Monday, February 26th.

How to Become a New Pot Stock Millionaire

Shares of MAIN stock traded down $0.24 on Friday, hitting $37.04. The stock had a trading volume of 100,483 shares, compared to its average volume of 338,079. The company has a quick ratio of 0.15, a current ratio of 0.15 and a debt-to-equity ratio of 0.21. Main Street Capital has a twelve month low of $34.37 and a twelve month high of $41.79. The firm has a market capitalization of $2,166.84, a price-to-earnings ratio of 12.40 and a beta of 0.96.

Main Street Capital (NYSE:MAIN) last issued its quarterly earnings results on Thursday, February 22nd. The financial services provider reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.01. Main Street Capital had a return on equity of 10.34% and a net margin of 82.93%. The business had revenue of $55.80 million for the quarter, compared to analyst estimates of $53.17 million. During the same quarter in the prior year, the firm posted $0.57 earnings per share. The firm’s revenue for the quarter was up 19.2% compared to the same quarter last year. equities analysts predict that Main Street Capital will post 2.42 EPS for the current fiscal year.

The business also recently declared a monthly dividend, which will be paid on Monday, April 16th. Shareholders of record on Wednesday, March 21st will be paid a $0.19 dividend. The ex-dividend date of this dividend is Tuesday, March 20th. This represents a $2.28 dividend on an annualized basis and a yield of 6.16%. Main Street Capital’s dividend payout ratio is 76.25%.

A number of hedge funds have recently bought and sold shares of the business. Burgundy Asset Management Ltd. grew its stake in Main Street Capital by 4.4% in the fourth quarter. Burgundy Asset Management Ltd. now owns 1,908,296 shares of the financial services provider’s stock valued at $75,817,000 after purchasing an additional 80,123 shares in the last quarter. Macquarie Group Ltd. lifted its holdings in Main Street Capital by 7.3% during the 3rd quarter. Macquarie Group Ltd. now owns 1,105,132 shares of the financial services provider’s stock worth $43,929,000 after buying an additional 75,462 shares during the period. M&T Bank Corp lifted its holdings in Main Street Capital by 1.6% during the 4th quarter. M&T Bank Corp now owns 478,304 shares of the financial services provider’s stock worth $19,004,000 after buying an additional 7,687 shares during the period. Van ECK Associates Corp lifted its holdings in Main Street Capital by 5.8% during the 3rd quarter. Van ECK Associates Corp now owns 403,372 shares of the financial services provider’s stock worth $16,034,000 after buying an additional 21,957 shares during the period. Finally, BlackRock Inc. lifted its holdings in Main Street Capital by 7.8% during the 4th quarter. BlackRock Inc. now owns 338,702 shares of the financial services provider’s stock worth $13,457,000 after buying an additional 24,620 shares during the period. Hedge funds and other institutional investors own 27.57% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Main Street Capital Co. (MAIN) Given Consensus Rating of “Hold” by Brokerages” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3293668/main-street-capital-co-main-given-consensus-rating-of-hold-by-brokerages.html.

Main Street Capital Company Profile

Main Street Capital Corporation (MSCC) is a principal investment firm. MSCC’s principal investment objective is to maximize its portfolio’s total return by generating current income from the Company’s debt investments and capital appreciation from its equity and equity related investments, including warrants, convertible securities and other rights to acquire equity securities in a portfolio company.

Analyst Recommendations for Main Street Capital (NYSE:MAIN)

Receive News & Ratings for Main Street Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Main Street Capital and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Q2 2018 EPS Estimates for TCF Financial Co.  Boosted by Analyst
Q2 2018 EPS Estimates for TCF Financial Co. Boosted by Analyst
Q2 2018 EPS Estimates for Wabtec Co. Decreased by B. Riley
Q2 2018 EPS Estimates for Wabtec Co. Decreased by B. Riley
Spirent  Insider Eric G. Hutchinson Purchases 206 Shares
Spirent Insider Eric G. Hutchinson Purchases 206 Shares
Q1 2018 EPS Estimates for Chesapeake Energy  Lowered by Imperial Capital
Q1 2018 EPS Estimates for Chesapeake Energy Lowered by Imperial Capital
ANI Pharmaceuticals  Stock Rating Lowered by BidaskClub
ANI Pharmaceuticals Stock Rating Lowered by BidaskClub
Achillion Pharmaceuticals  Upgraded to “Buy” by Zacks Investment Research
Achillion Pharmaceuticals Upgraded to “Buy” by Zacks Investment Research


© 2006-2018 Ticker Report. Google+.